*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*                                                                     *x*
*x*            Copyright (C) 1990 University of Pennsylvania            *x*
*x*                                                                     *x*
*x*    The data in this file are part of a preliminary version of the   *x*
*x*    Penn Treebank Corpus.  Any research using this corpus or based   *x*
*x*    on it should acknowledge that fact, as well as the preliminary   *x*
*x*    nature of the corpus.                                            *x*
*x*                                                                     *x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*



======================================

[ Some/DT people/NNS ]
with/IN 
[ the/DT immune-system/NN cancer/NN ]
known/VBN as/IN 
[ B-cell/NN lymphoma/NN ]
have/VBP been/VBN found/VBN to/TO have/VB 
[ tumor/NN ]
``/`` 
[ markers/NNS ]
''/'' 
[ that/WDT ]
react/VBP to/TO 
[ antibodies/NNS ]
custom-made/VBN for/IN 
[ other/JJ patients/NNS ]
./. 

[ The/DT discovery/NN ]
raises/VBZ 
[ hopes/NNS ]
that/IN 
[ doctors/NNS ]
may/MD develop/VB 
[ an/DT armory/NN ]
of/IN 
[ ready-made/JJ biological/JJ weapons/NNS ]
against/IN 
[ the/DT disease/NN ]
./. 

======================================

[ B-cell/NN lymphoma/NN ]
is/VBZ 
[ an/DT often-fatal/JJ tumor/NN ]
of/IN 
[ lymph/NN tissue/NN ]

[ that/WDT ]
affects/VBZ about/RB 
[ 100,000/CD Americans/NNP ]
./. 

In/IN 
[ lymphoma/NN ]
,/, 
[ malignant/JJ B/NN cells/NNS ]
are/VBP frozen/VBN at/IN 
[ an/DT immature/JJ stage/NN ]
and/CC ca/MD n't/RB produce/VB 
[ antibodies/NNS ]
against/IN 
[ disease/NN ]
./. 

[ The/DT incidence/NN ]
of/IN 
[ such/JJ cancer/NN ]
is/VBZ growing/VBG ,/, in/IN 
[ part/NN ]
because/IN of/IN 
[ its/PRP$ occurrence/NN ]
among/IN 
[ patients/NNS ]
with/IN 
[ acquired/JJ immune/JJ deficiency/NN syndrome/NN ]
,/, or/CC 
[ AIDS/NNP ]
./. 

======================================

[ Malignant/NN B-cells/NNS ]
carry/VBP 
[ certain/JJ proteins/NNS ]
,/, called/VBN ``/`` 
[ idiotypes/NNS ]
,/, ''/'' on/IN 
[ their/PRP$ surface/NN ]

[ that/WDT ]
are/VBP 
[ the/DT key/NN ]
to/TO 
[ an/DT individual/NN 's/POS tumor/NN type/NN ]
,/, much/RB as/IN 
[ a/DT fingerprint/NN ]
identifies/VBZ 
[ a/DT person/NN ]
./. 

[ Researchers/NNS ]
have/VBP used/VBN 
[ such/JJ markers/NNS ]
as/IN 
[ targets/NNS ]
for/IN 
[ custom-made/JJ monoclonal/JJ antibodies/NNS ]
to/TO bind/VB and/CC block/VB 
[ tumor/NN growth/NN ]
./. 

But/CC 
[ such/JJ custom/NN ]
``/`` 
[ anti-idiotypes/NNS ]
''/'' can/MD take/VB 
[ a/DT year/NN ]
to/TO develop/VB ./. 

Thus/RB 
[ they/PRP ]
have/VBP been/VBN unavailable/JJ to/TO 
[ people/NNS ]
with/IN 
[ advanced/JJ lymphoma/NN ]
and/CC limited/JJ 
[ life/NN expectancy/NN ]
./. 

======================================

But/CC 
[ researchers/NNS ]
at/IN 
[ Stanford/NNP University/NNP ]
and/CC 
[ Idec/NNP Pharmaceuticals/NNP Corp./NNP ]
of/IN 
[ La/NNP Jolla/NNP ]
,/, 
[ Calif./NNP ]
,/, 
[ this/DT week/NN ]
reported/VBD 
[ a/DT finding/NN ]

[ that/WDT ]
could/MD make/VB 
[ such/JJ tools/NNS ]
accessible/JJ to/TO 
[ a/DT broader/JJR group/NN ]
./. 

In/IN 
[ the/DT test/NN tube/NN ]
,/, up/IN to/TO 
[ one-third/NN ]
of/IN 
[ lymphoma/NN patients/NNS '/POS tumors/NNS ]
reacted/VBD with/IN 
[ customized/JJ antibodies/NNS ]
developed/VBN for/IN 
[ other/JJ people/NNS ]
./. 

[ Such/JJ shared/JJ tumor/NN markers/NNS ]
were/VBD previously/RB found/VBN to/TO exist/VB among/IN 
[ patients/NNS ]
with/IN 
[ chronic/JJ lymphocytic/JJ leukemia/NN ]
./. 

======================================

``/`` 
[ What/WP ]

[ we/PRP ]
do/VBP n't/RB know/VB yet/RB is/VBZ whether/IN {/( 
[ such/JJ antibodies/NNS ]
 }/) will/MD have/VB 
[ a/DT beneficial/JJ effect/NN ]
on/IN 
[ patients/NNS ]
''/'' other/JJ than/IN 
[ those/DT ]
for/IN 
[ whom/WP ]

[ they/PRP ]
were/VBD created/VBN ,/, said/VBD 
[ Ronald/NNP Levy/NNP ]
,/, 
[ a/DT professor/NN ]
of/IN 
[ medicine/NN ]
at/IN 
[ Stanford/NN ]
and/CC 
[ senior/JJ author/NN ]
of/IN 
[ a/DT paper/NN ]
on/IN 
[ the/DT study/NN ]
appearing/VBG in/IN 
[ today/NN 's/POS edition/NN ]
of/IN 
[ the/DT New/NNP England/NNP Journal/NNP ]
of/IN 
[ Medicine/NNP ]
./. 

[ Dr./NNP Levy/NNP ]
is/VBZ 
[ an/DT Idec/NNP consultant/NN ]
and/CC 
[ shareholder/NN ]
./. 

======================================

[ Dr./NNP Levy/NNP ]
said/VBD 
[ questions/NNS ]
remain/VBP about/IN why/WRB 
[ such/JJ tumor/NN proteins/NNS ]
,/, once/RB thought/VBD 
[ unique/JJ ]
,/, 
[ cross-react/VBP ]
with/IN 
[ antibodies/NNS ]
created/VBN to/TO block/VB 
[ other/JJ people/NNS 's/POS tumors/NNS ]
./. 

But/CC 
[ it/PRP ]
raises/VBZ 
[ the/DT hope/NN ]
that/IN 
[ companies/NNS ]
might/MD develop/VB 
[ whole/JJ libraries/NNS ]
of/IN 
[ antibodies/NNS ]
,/, with/IN 
[ much/RB broader/JJR clinical/JJ ]
and/CC 
[ commercial/JJ importance/NN ]
,/, 
[ Idec/NNP ]
said/VBD ./. 

======================================

``/`` 
[ I/PRP ]
'm/VBP really/RB excited/JJ about/IN 
[ it/PRP ]
because/IN up/IN until/IN now/RB 
[ we/PRP ]
've/VBP only/RB been/VBN able/JJ to/TO {/( treat/VB }/) on/IN 
[ people/NNS ]

[ who/WP ]
have/VBP 
[ time/NN ]
to/TO wait/VB ,/, ''/'' 
[ Dr./NNP Levy/NNP ]
said/VBD in/IN 
[ an/DT interview/NN ]
./. 

``/`` But/CC if/IN 
[ these/DT pre-existing/JJ antibodies/NNS ]
work/VBP ,/, 
[ we/PRP ]
could/MD open/VB 
[ it/PRP ]
up/RP to/TO 
[ many/JJ more/JJR patients/NNS ]
./. 

''/'' 
======================================

[ Other/JJ cancer/NN experts/NNS ]
cautioned/VBD that/IN 
[ such/JJ benefits/NNS ]
have/VBP yet/RB to/TO be/VB proven/VBN in/IN 
[ the/DT clinic/NN ]
,/, but/CC 
[ they/PRP ]
said/VBD 
[ the/DT Stanford-Idec/NNP team/NN ]
had/VBD taken/VBN 
[ a/DT real/JJ step/NN ]
toward/IN making/VBG 
[ the/DT benefits/NNS ]
of/IN 
[ research/NN ]
more/RBR practical/JJ ./. 
